The combination of boron neutron-capture therapy and immunoprophylaxis for advanced intracerebral gliosarcomas in rats.
Glioblastoma multiforme (GBM) is the most common primary human brain tumor. About 7000 new cases are diagnosed yearly in the USA and GBM is almost invariably fatal within a few years after it is diagnosed. Despite current neurosurgical and radiotherapeutic tumor cytoreduction methods, in most cases occult foci of tumor cells infiltrate surrounding brain tissues and cause recurrent disease. Therefore the combination of neurosurgical and radiotherapeutic debulking methods with therapies to inhibit occult GBM cells should improve prognosis. In this study we have combined boron neutron-capture therapy (BNCT), a novel binary radiotherapeutic treatment modality that selectively irradiates tumor tissue and largely spares normal brain tissue, with immunoprophylaxis, a form of active immunization initiated soon after BNCT treatment, to treat advanced, clinically relevantly-sized brain tumors in rats. Using a malignant rat glioma model of high immunogenicity, the 9L gliosarcoma, we have shown that about half of the rats that would have died after receiving BNCT debulking alone, survived after receiving BNCT plus immunoprophylaxis. Further, most of the surviving rats display immunological-based resistance to recurrent 9LGS growth six months or more after treatment. To our knowledge this study represents the first time BNCT and immunoprophylaxis have been combined to treat advanced brain tumors in rats.
Smilowitz
H M
HM
Department of Pharmacology, University of Connecticut Health Center, Farmington 06030-6125, USA. smilowitz@NSO1.UCHC.EDU
Micca
P L
PL
Nawrocky
M M
MM
Slatkin
D N
DN
Tu
W
W
Coderre
J A
JA
D000818:Animals; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000276:immunology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018316:Gliosarcoma / Q000276:immunology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016233:Immunotherapy, Active; D008297:Male; D009364:Neoplasm Recurrence, Local; D051381:Rats; D011916:Rats, Inbred F344; D013047:Specific Pathogen-Free Organisms
D019496:Cancer Vaccines